Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SHR-A1921 |
Trade Name | |
Synonyms | SHR A1921|SHRA1921|SHRA 1921|SHR-1921 |
Drug Descriptions |
SHR-A1921 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially induces tumor cell killing and and inhibits growth of tumors expressing TROP2 (Cancer Res (2023) 83 (8_Supplement): LB030, Cancer Res (2023) 83 (8_Supplement): CT181). |
DrugClasses | TROP2 Antibody 14 |
CAS Registry Number | NA |
NCIT ID | C193454 |